Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab.
- DOI
- 10.1007/s00415-022-11084-0
- Published
- 2022 Aug
- Container
- Journal of neurology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00415-022-11084-0,
title = {Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab.},
author = {Sherlock SP and Palmer J and Wagner KR and Abdel-Hamid HZ and Bertini E and Tian C and Mah JK and Kostera-Pruszczyk A and Muntoni F and Guglieri M and Brandsema JF and Mercuri E and Butterfield RJ and McDonald CM and Charnas L and Marraffino S},
year = {2022},
journal = {Journal of neurology},
doi = {10.1007/s00415-022-11084-0},
url = {https://doi.org/10.1007/s00415-022-11084-0}
}RIS
TY - JOUR TI - Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab. AU - Sherlock SP AU - Palmer J AU - Wagner KR AU - Abdel-Hamid HZ AU - Bertini E AU - Tian C AU - Mah JK AU - Kostera-Pruszczyk A AU - Muntoni F AU - Guglieri M AU - Brandsema JF AU - Mercuri E AU - Butterfield RJ AU - McDonald CM AU - Charnas L AU - Marraffino S PY - 2022 JO - Journal of neurology DO - 10.1007/s00415-022-11084-0 UR - https://doi.org/10.1007/s00415-022-11084-0 ER -
APA
SP, S., J, P., KR, W., HZ, A., E, B., C, T., JK, M., A, K., F, M., M, G., JF, B., E, M., RJ, B., CM, M., L, C., & S, M. (2022). Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab.. Journal of neurology. https://doi.org/10.1007/s00415-022-11084-0
Source records
- pubmed · retrieved 2026-09-27T10:26:40.306Z
- europe-pmc · retrieved 2026-09-27T10:26:40.321Z